IP Library Granted Patent US 8,206,927
Granted Patent B2
US 8,206,927 · App. 12/524,136 · Granted Jun 26, 2012

Method for accurate assessment of DNA quality after bisulfite treatment

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,206,927
App. No.
12/524,136
Granted
Jun 26, 2012
Kind
B2
Abstract

The present invention is directed to methods useful for determining DNA quality after bisulfite treatment. The methods include a PCR-based assay, which allows ab-initio assessment of the DNA quality after bisulfite treatment and can help to prevent inaccurate quantitative measurement resulting from poor bisulfite treatment.

Claims (32)

1. A method to determine the maximum amplicon size for DNA in a sample after bisulfite treatment that will yield accurate quantitative measurements, comprising:

a) treating the sample with bisulfite;

b) performing PCR using a primer set that amplifies at least two amplicons from a control region, wherein the amplicons increase in length in small increments and each amplicon is substantially covered by the next longer amplicon;

c) analyzing at least three CpG sites that are common to all of the amplicons of step b) in regards to amplification success and statistical variability; and

d) determining which of the amplicon sizes is suitable for a given sample, wherein high amplification success and low statistical variability is indicative of an amplicon size that yields accurate quantitative measurements.

2. A method to determine the optimal methylation conditions across a range of amplicon sizes for DNA in a sample, comprising:

a) treating the sample with bisulfite;

b) performing PCR using a primer set that amplifies at least two amplicons from a control region, wherein the amplicons increase in length in small increments and each amplicon is substantially covered by the next longer amplicon;

c) modifying at least one of the methylation conditions to introduce variable methylation conditions;

d) analyzing at least three CpG sites that are common to all of the amplicons of step b) in regards to amplification success and statistical variability; and

e) determining which methylation conditions are optimal across a range of amplicon sizes for DNA in a sample, wherein high amplification success and low statistical variability is indicative of optimal methylation conditions that yield accurate quantitative measurements.

3. The method of claim 2 , wherein the methylation conditions are selected from the group consisting of sample handling methods, bisulfite treatment methods, PCR conditions, methylation-related biochemistry methods and detection methods.

4. The method of claim 3 , wherein the PCR conditions are selected from the group consisting of temperature, incubation time and PCR primer concentration.

5. The method of claim 1 , wherein the bisulfite concentration of step a) is the same or substantially the same as the bisulfite concentration of a target assay.

6. The method of claim 1 , wherein the PCR conditions of step b) are the same or substantially the same as the PCR conditions of a target assay.

7. The method of claim 1 , wherein the primers of step b) bind to binding sites that are free of CpG sites.

8. The method of claim 1 , wherein the PCR reaction of step b) is done in a single reaction.

9. The method of claim 1 , wherein the PCR reaction of step b) amplifies at least 3 amplicons from a control region.

10. The method of claim 1 , wherein the PCR reaction of step b) amplifies at least 4 amplicons from a control region.

11. The method of claim 1 , wherein the shortest amplicon is at least 100 base pairs.

12. The method of claim 1 , wherein the longest amplicon is no more than 900 base pairs.

13. The method of claim 1 , wherein the amplicons are increased in increments between about 100 and 150 base pairs.

14. The method of claim 1 , wherein the amplicons cover substantially the same region.

15. The method of claim 1 , wherein the control region comprises at least 3 CpG sites, wherein each CpG site has a known methylation ratio.

16. The method of claim 1 , wherein the control region is the promoter region of IGF2/H19.

17. A method to determine methylation conditions which yield results more accurate across a range of amplicon sizes for DNA in a sample, comprising:

a) treating the sample with bisulfite;

b) performing PCR using a primer set that amplifies at least two amplicons from a control region, wherein the amplicons increase in length in small increments and each amplicon is substantially covered by the next longer amplicon;

c) modifying at least one of the methylation conditions to introduce variable methylation conditions;

d) analyzing at least three CpG sites that are common to all of the amplicons of step b) in respect to amplification success and statistical variability; and

e) determining which methylation conditions yield more accurate results across a range of amplicon sizes for DNA in a sample, wherein high amplification success and low statistical variability is indicative of methylation conditions that yield more accurate quantitative measurements;

wherein the methylation conditions are selected from the group consisting of sample handling, bisulfite treatment methods, amplification conditions, and methylation detection methods.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Dec 7, 2021
From: MIDCAP FUNDING IV TRUST
To: AGENA BIOSCIENCE, INC.
Reel/Frame 058741/0005 →
RELEASE OF SECURITY INTEREST IN REEL 041621 FRAME 0548 Recorded Jul 13, 2021
From: MIDCAP FINANCIAL TRUST
To: AGENA BIOSCIENCE, INC.
Reel/Frame 056860/0557 →
SECURITY INTEREST Recorded Mar 21, 2017
From: AGENA BIOSCIENCE, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 042050/0888 →
SECURITY INTEREST Recorded Feb 3, 2017
From: AGENA BIOSCIENCE, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 041621/0548 →